IFN-γ and TNF-α in combination with trastuzumab and pertuzumab mediate the restoration of MHC class I expression and promotion of HER2-CD8+ T cell targeting against HER2 positive cancers (Datta et al., 2015d; Figure 2). This evidence concerns the gene TNF and cancer.